Establishment and Characterization of Acquired Resistance to Platinum Anticancer Drugs in Human Ovarian Carcinoma Cells
- 1 January 1995
- journal article
- research article
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 86 (1) , 88-94
- https://doi.org/10.1111/j.1349-7006.1995.tb02992.x
Abstract
To investigate differences in resistance to cis‐diamminedichloroplatinum(II) (CDDP) and diammine (1,1‐cyclobutanecarboxylato)platinum(II) (CBDCA), and their newly developed derivative, ((—)‐(R)‐2‐aminomethylpyrrolidine (1,1‐cyclobutanedicarboxylato)platinum (II)) (DWA2114R), four types of resistant cell lines were established from a parental cell line (NOS2) of a serous cystadeno‐carcinoma of the ovary. The cross‐resistance of CDDP‐resistant cells (NOS2CR1 and NOS2CR2) to DWA2114R was slight (only 25% of the resistance to CDDP), and no cross‐resistance was observed to anticancer drugs other than the CDDP derivative, except to camptothecin (CPT‐11) in the case of NOS2CR2 cells. The cross‐resistance of CBDCA‐resistant cells (NOS2CBR) to DWA2114R was slight (only about 1/3 of the resistance to CBDCA), and no cross‐resistance was observed among anticancer drugs other than the CDDP derivative. On the other hand, DWA2114R‐resistant cells (NOS2DR) showed a high cross‐resistance to CDDP, CBDCA, etoposide (VP‐16), and CPT‐11. Intracellular accumulations of CDDP and CBDCA were markedly reduced in NOS2CR1, NOS2CR2, and NOS2CBR cells compared to those in NOS2 cells, but were reduced only slightly in NOS2DR cells. Intracellular accumulation of DWA2114R was reduced somewhat in the four types of resistant cells. Glutathione S‐transferase activity was not increased in any of the four types of resistant cells, and intracellular GSH concentration was increased only in NOS2CR2 cells (by 2.6 fold). From these results, we consider that the resistance mechanisms against CDDP and CDBCA are similar, and reduction of intracellular drug accumulations is a significant factor. Resistance to DWA2114R differed from resistance to CDDP and CBDCA in both cross‐resistance spectrum and resistance mechanism, indicating that reduction in intracellular drug accumulation is not the major resistance mechanism.Keywords
This publication has 33 references indexed in Scilit:
- The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agentsBiochemical Pharmacology, 1993
- Reduced drug accumulation in a newly established human lung squamous-carcinoma cell line resistant to cis-diamminedichloroplatinum(II)Biochemical Pharmacology, 1992
- High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.Proceedings of the National Academy of Sciences, 1992
- Antitumor Activity and Cellular Accumulation of a New Platinum Complex, (—)‐(R)‐2‐Aminomethylpyrrolidine(1,l‐cyclobutanedicarboxylato)platinum(II) Monohydrate, in Cisplatin‐sensitive and ‐resistant Murine P388 Leukemia CellsJapanese Journal of Cancer Research, 1992
- Expression of recombinant glutathione S-transferase pi, Ya, or Yb1 confers resistance to alkylating agents.Proceedings of the National Academy of Sciences, 1990
- Enhancement of cisplatin (DDP) antitumor activity by 3-aminobenzamide in rat ovarian tumors sensitive and resistant to DDP in vivoCancer Chemotherapy and Pharmacology, 1990
- Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDaAnalytical Biochemistry, 1987
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences, 1979
- Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Applications to mammalian blood and other tissuesAnalytical Biochemistry, 1969